Text Size

Prognostic Value of Stem Cell Related Markers

The recruitment status of this study is unknown because the information has not been verified recently.
Verified December 2010 by The Baruch Padeh Medical Center, Poriya.
Recruitment status was  Not yet recruiting
Sponsor:
Information provided by:
The Baruch Padeh Medical Center, Poriya
ClinicalTrials.gov Identifier:
NCT01265225
First received: December 21, 2010
Last updated: December 22, 2010
Last verified: December 2010
History of Changes
  Purpose

The goal of the investigators study is to identify a prognostic marker that will evaluate the probability of recurrence in patients with stage 0-II breast cancer following surgery to remove the tumor.


Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Official Title: Prognostic Value of Stem Cell Related Markers CD24, CD44, CD326 and EPCR, for Predicting Breast Cancer Recurrence in Tumor Stages 0-II

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by The Baruch Padeh Medical Center, Poriya:

Estimated Enrollment: 100
Study Start Date: February 2011
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: February 2013 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

100 tumor specimens from women with grade 0-11 ductal breast cancer

Criteria

Inclusion Criteria:

  • Ductal Carcinoma in Situ
  • DCIS + Microinvasion stages 1 or 11 without positive lymph nodes

Exclusion Criteria:

  • tumor specimen with higher than grade II
  • BRACA 1 or BRACA 2 mutation
  • Neoadjuvant chemotherapy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01265225

Locations
Israel
Baruch PMC
Poriya, Lower galilee, Israel, 15208
Sponsors and Collaborators
The Baruch Padeh Medical Center, Poriya
  More Information

No publications provided

Responsible Party: Dr. I. Schnirer, Baruch Padeh Poriya Medical Center
ClinicalTrials.gov Identifier: NCT01265225     History of Changes
Other Study ID Numbers: 10.CTIL
Study First Received: December 21, 2010
Last Updated: December 22, 2010
Health Authority: Israel: Ministry of Health

Keywords provided by The Baruch Padeh Medical Center, Poriya:
breast cancer stages 0-II

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on May 16, 2013